The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Novel HCK inhibitor has a synergistic effect with azacytidine or cytarabine in AML cells
Sara Olalla Saad, PhD, University of Campinas & Hemocentro – Unicamp, Campinas, Brazil, discusses a novel chemical compound inhibitor of hematopoietic cell kinase (HCK). She explains how this was found to have antiproliferative activity in leukemic cells without altering the cell death and survival rate of normal cells, having a synergistic effect with azacitidine or cytarabine, for acute myeloid leukemia (AML), and discusses how they are moving testing of this agent forwards. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
